The Effects of Magnesium (Mg) Supplement and Alternate Maxillary Expansion and Constriction (Alt-… (NCT07309640) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
The Effects of Magnesium (Mg) Supplement and Alternate Maxillary Expansion and Constriction (Alt-RAMEC) in Patient With Transverse Maxillary Deficiency (TMD)
Iraq38 participantsStarted 2026-01-01
Plain-language summary
This randomized clinical trial evaluates the effect of combining magnesium supplementation with an orthodontic technique called Alternate Maxillary Expansion and Constriction (Alt-RAMEC) using a Micro-implant Assisted Rapid Palatal Expansion (MARPE) appliance to treat adults (18-30 years) with transverse maxillary deficiency (TMD). TMD is a condition where the upper jaw is narrower than normal, which can affect bite and facial development.
The study involves two groups: one receiving the Alt-RAMEC protocol with MARPE alone, and the other receiving the same protocol alongside oral magnesium supplements. The effectiveness of these treatments will be compared by assessing changes in dental and skeletal structures through imaging techniques and evaluating muscle function. Participants will also report their pain and discomfort levels during the treatment.
This research aims to understand whether magnesium supplementation can enhance the effects of Alt-RAMEC treatment, improve patient outcomes, and reduce discomfort associated with orthodontic procedures.
Who can participate
Age range18 Years – 25 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. All participants were young adults, from the 18- 25 age group (males or females).
✓. There is a maxillary skeletal deficiency in every patient. (Anteroposterior deficiency, transverse bilateral/unilateral deficiency)
✓. All teeth erupted without any abnormalities in term of shape and size.
✓. Good oral hygiene and non-smoking habits.
Exclusion criteria
✕. History of previous orthodontic treatment or maxillary expansion
✕. Patients with severe progressive periodontal disease
✕. Patients with severe craniomaxillofacial deformities such as cleft lip and palate
✕. Mid palatal fusion without successful expansion
✕. First molar absent or impacted in the patient.
✕. Patients who have bone loss, gingival recession, or persistent gingival inflammation.
What they're measuring
1
The Primary Outcome Measure title for this clinical study is: Change in Transverse Maxillary Dimensions and Muscular Activity Following Alt-RAMEC Protocol with or without Magnesium Supplementation
Timeframe: The Time Frame for the primary outcome measure in this clinical trial is: Pre-treatment (T0) to Post-treatment (T1), including the active expansion period after 12 weeks of alternate expansion and constriction
✕. History of a life-threatening medical condition, such as diabetes mellitus, or a chronic disease such as organ transplant rejection or cancer in patients receiving chemotherapy or radiation therapy and high risk of infections.